Cardio Diagnostics Holdings (CDIO) Research & Development (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Research & Development of $129776.0 for Q1 2026, up 9.25% sequentially from $118784.0 in Q1 2025, and up 9.25% YoY from $118784.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Research & Development (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Research & Development for 5 years, with the latest figure at $129776.0 in Q1 2026.
- Quarterly Research & Development rose 9.25% year-over-year to $129776.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 5.67% YoY) and the FY2025 annual result came in at $641212.0, down 47.95% from the prior year.
- Research & Development climbed to $129776.0 in Q1 2026 per CDIO's latest filing, from $118784.0 in the prior quarter.
- Over five years, Research & Development peaked at $1.1 million in Q4 2024 and troughed at -$25125.0 in Q4 2022.
- A 5-year average of $112391.0 and a median of $29207.0 in 2022 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 5123.44% in 2024, down 84.6% in 2024.
- Over 5 years, Research & Development stood at -$25125.0 in 2022, then surged by 182.88% to $20824.0 in 2023, then soared by 5123.44% to $1.1 million in 2024, then sank by 89.08% to $118784.0 in 2025, then gained by 9.25% to $129776.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $129776.0, $118784.0, and $1.1 million for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | 190,183.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 190,183.00 |
| Mar 31, 2026 | 129,776.00 |
| Mar 31, 2025 | 118,784.00 |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | 5,247.00 |
| Jun 30, 2024 | 57,779.00 |
| Mar 31, 2024 | 10,840.00 |
| Dec 31, 2023 | 20,824.00 |
| Sep 30, 2023 | 34,067.00 |
| Jun 30, 2023 | 31,608.00 |
| Mar 31, 2023 | 49,551.00 |
| Dec 31, 2022 | -25,125.00 |
| Sep 30, 2022 | 3,190.00 |
| Jun 30, 2022 | 26,806.00 |
| Mar 31, 2022 | 22,398.00 |